Hepatitis C
Conditions
Brief summary
Exercise is one of the most vital components of health maintenance. Exercising regularly maintains the cardiovascular system health, promotes the health of liver, and declines the risks of complications induced by CHCV. Since overweight is the main risk factor for IR and type 2 DM which may speed the liver disease progression among HCV patients, exercise is very important for maintenance and loss of weight. Further, exercise can relieve the side effects of medications of HCV, improve immunity, promote a sense of well-being, reduce levels of chronic fatigue, improve blood oxygen levels and increase the endorphins excretion which makes the patients fully energized (Elgendi, Shebl A, Sliem M, and Gary FA, 2018). Studies on exercise effect in patients with CHCV are quite scarce (de Sousa Fernandes et al., 2019). Decreased leptin levels by exercise positively modulate insulin signaling and inhibit pathology progression (Anaruma et al., 2019). Since studies investigated physical activity effect on regulating HCV related leptin levels are very little, the present study aimed to explore the response of serum leptin and liver enzymes to aerobic exercise in nondiabetic overweight men with CHCV.
Detailed description
The study group (n=20) received three sessions of aerobic walking exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down. The control group (n=20) will receive no training.
Interventions
BEHAVIORALaerobic treadmill exercise
The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Men with hepatitis C patients at least from 6 months * BMI ranged ≥ 25 to \< 30 kg/m2. * fasting blood glucose level (FBG) \< 100 mg/dl. * waist circumference \< 102 cm.
Exclusion criteria
* Besides the excluded individuals who participated in any form of physical training in the last 6 months, excluded patients by a physician will be patients with acute or other hepatitis types, cirrhotic or hepatocellular carcinoma, renal or respiratory problems, cardiovascular and neurologic diseases, and hypertension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Leptin | It will be after 12-week training | It will be measured in plasma |
| Liver enzymes | liver enzymes will be after 12-week training | Serum alanine and aspartate transaminases (AST), (ALT) will be measured in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| weight | It will be after 12-week training | With an empty bladder and stomach, weight will be measured for every participant |
| Waist circumference (WC) | It will be after 12-week training | WC will be measured with an inelastic tape at the umbilicus level |
| fasting blood glucose (FBG) | It will be after 12-week training | FBG will be measured by On Call ® Plus Acon, REF G113- 214, made in China |
Countries
Egypt
Contacts
Primary ContactAli Ismail, lecturer
Outcome results
None listed